Thrombopoietin receptor agonists in ITP: current status and future outlooks

Описание к видео Thrombopoietin receptor agonists in ITP: current status and future outlooks

Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses the role of thrombopoietin (TPO) receptor agonists, including avatrombopag, eltrombopag, and romiplostim, in the treatment of immune thrombocytopenia (ITP). Dr Al-Samkari highlights the long-term safety demonstrated by these agents, and further explains the value of novel TPO receptor agonists being evaluated. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке

Похожие видео